CAMBRIDGE, Mass., Sept. 3 /PRNewswire/ -- Satori Pharmaceuticals Incorporated, a privately held developer of therapeutics for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders, today announced that Steven Holtzman, CEO and co-founder of Infinity Pharmaceuticals, has joined its Board of Directors.
Prior to co-founding Infinity in 2001, from 1994-2001 Steve served as an early leader and the Chief Business Officer of Millennium Pharmaceuticals. At Millennium he was a principal architect in crafting successful multi-million dollar technology deals which were instrumental in building a leading biotechnology company. Prior to joining Millennium, from 1986-1994, Mr. Holtzman was a founder and Executive Vice President of DNX Corporation, the first commercial developer of transgenic animal technology. Prior to DNX, in the early 1980s, Mr. Holtzman conceived of and was the founding Executive Director of the Ohio Edison Program, the nation's first state government program directed to achieving economic development through funding young technology-based ventures and university/industry collaborative research and development efforts.
"I am delighted and feel privileged to join Satori's team of world leaders in the field of Alzheimer's research and drug discovery," says Mr. Holtzman. "As recent data from the Alzheimer's Disease Neuroimaging Initiative clearly demonstrate, Satori's flagship program focuses on the most compelling target for preventing the progression of Alzheimer's."
On the Satori board, Mr. Holtzman joins Dr. Ives; Dr. Thomas Salzmann, Chairman of the Board and former EVP of Preclinical Development at Merck, and Board member at Sirtris and Concert Pharmaceuticals; Mr. Chris Ehrlich, General Partner at InterWest Partners; Mr. Ed Mathers, Partner at NEA; Dr. Ilan Zipkin, Partner at Prospect Venture Partners; Dr. Bennett Shapiro, PureTech Senior Partner and former EVP of Basic and External Research at Merck; and Ms. Daphne Zohar, PureTech Managing Partner.
Satori Pharmaceuticals is committed to the development of disease modifying therapies for Alzheimer's and Parkinson's diseases through the targeting of the key neurotoxic mediators and pathways of neurodegenerative diseases.
Satori Pharmaceuticals Incorporated
